Please sign in to follow a disease.
Dianthus Therapeutics
Clinical trials sponsored by Dianthus Therapeutics, explained in plain language.
Biotech developing complement-targeted therapies for rare diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug could reduce need for infusions in nerve disorder Results expected Dec 2026 (estimated) May already have reported ↗
-
New drug aims to stop CIDP relapses in its tracks
Disease control Recruiting nowThis Phase 3 trial tests whether the drug claseprubart (DNTH103) can prevent relapses in adults with CIDP, a nerve disorder that causes weakness and disability. About 256 participants will receive either the drug or a placebo. The main goal is to see how long it takes for symptom…
Phase 3 • Sponsor: Dianthus Therapeutics • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug aims to ease daily struggles of myasthenia gravis
Disease control Recruiting nowThis phase 3 trial tests whether claseprubart (DNTH103) can improve symptoms of generalized myasthenia gravis, a condition causing muscle weakness. About 195 adults with a specific antibody type are randomly assigned to receive the drug or a placebo. The main goal is to see if th…
Phase 3 • Sponsor: Dianthus Therapeutics • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC